Bank of Montreal Can Has $7.12 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bank of Montreal Can lowered its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 408,015 shares of the company’s stock after selling 5,744 shares during the quarter. Bank of Montreal Can’s holdings in Teva Pharmaceutical Industries were worth $7,124,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Teva Pharmaceutical Industries by 3.5% in the first quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock valued at $11,648,000 after buying an additional 28,071 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Teva Pharmaceutical Industries by 21.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 201,849 shares of the company’s stock worth $2,849,000 after purchasing an additional 36,295 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Teva Pharmaceutical Industries by 6.1% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 72,127 shares of the company’s stock valued at $1,036,000 after purchasing an additional 4,131 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 105.7% in the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after purchasing an additional 1,741 shares in the last quarter. Finally, DNB Asset Management AS boosted its position in shares of Teva Pharmaceutical Industries by 9.6% during the second quarter. DNB Asset Management AS now owns 160,302 shares of the company’s stock worth $2,605,000 after buying an additional 14,001 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $16.65 on Tuesday. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock has a market cap of $18.86 billion, a price-to-earnings ratio of -19.59, a PEG ratio of 1.30 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 12-month low of $9.35 and a 12-month high of $19.31. The business has a 50 day moving average of $17.54 and a 200-day moving average of $17.36.

Analysts Set New Price Targets

TEVA has been the subject of a number of recent research reports. UBS Group upped their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Barclays raised their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Insiders Place Their Bets

In other news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.